You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
A tick-borne disease working group recommends the federal government explore using new technologies and repurposing existing ones to improve diagnosis.
Quest Diagnostics and Oxford Immunotec Global announced this week that Quest has completed its previously announced acquisition of Oxford Immunotec's US laboratory services business.
Earlier this week, the company closed the sale of its US laboratory business to Quest DIagnostics for $170 million in cash.
Some see challenges ahead for Quest in scaling Oxford Immunotec's T-Spot.TB to compete against Qiagen's market-leading QuantiFERON-TB.
The acquisition is expected to close in the fourth quarter and to increase US access to Oxford Immunotec Global's T-Spot.TB tuberculosis test.
The company posted $29.3 million in revenues for the quarter, including $25 million from its tuberculosis business, which grew 17 percent year over year.
Month over month, the 360Dx Index beat the Dow Jones Industrial Average, the Nasdaq Composite, and the Nasdaq Biotech Index.
The firm said that sales growth was impacted by immigration headwinds, severe winter weather in the US, and unfavorable order timing in Asia.
The company claims its test can detect the Lyme-linked chemokine CXCL13 in human cerebrospinal fluid within 20 minutes.
The agency cleared two Roche tests that run on its Cobas systems. One does Chlamydia trachomatis and Neisseria gonorrhoeae testing and the other does hematology testing.